Skip to main content
SpringerLink
Log in

Do NALP5 antibodies correlate with hypoparathyroidism in patients with APS-1?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

Abstract

Hypoparathyroidism is the most common endocrine disorder detected in patients with autoimmune polyendocrine syndrome type 1 (APS-1); however, a parathyroid-specific autoantibody has not yet been identified. Alimohammadi et al. have screened a human parathyroid complementary DNA library with serum samples from patients with APS-1 and detected NACHT leucine-rich-repeat protein 5 (NALP5) immunoreactivity in 49% of patients with APS-1-associated hypoparathyroidism. When measured with a novel fluid-phase radioimmunoassay, these autoantibodies were found to be highly specific for the hypoparathyroid component of APS-1. In addition, NALP5 was predominantly expressed in the parathyroid gland. In this Practice Point commentary, I discuss the mechanistic and diagnostic implications of this finding for patients with APS-1. The natural history of NALP5 autoantibody expression in relation to the development of hypoparathyroidism is currently unclear. Furthermore, the positive and negative predictive value of NALP5 autoantibodies for the prediction of hypoparathyroidism among patients with APS-1 still needs to be defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Perheentupa J (2006) Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 91: 2843–2850

    Article  CAS  Google Scholar 

  2. Villaseñor J et al. (2005) AIRE and APECED: molecular insights into an autoimmune disease. Immunol Rev 204: 156–164

    Article  Google Scholar 

  3. Taubert R et al. (2007) Highly variable expression of tissue-restricted self-antigens in human thymus: implications for self-tolerance and autoimmunity. Eur J Immunol 37: 838–848

    Article  CAS  Google Scholar 

  4. Meager A et al. (2006) Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3: e289

    Article  Google Scholar 

  5. Alimohammadi M et al. (2008) Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 358: 1018–1028

    Article  CAS  Google Scholar 

  6. Wenzlauv JM et al. (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104: 17040–17045

    Article  Google Scholar 

  7. Eisenbarth SC et al. (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122–1126

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Barbara Davis Center for Childhood Diabetes, 1775 North Ursula Street, Aurora, CO 80010, USA george.eisenbarth@uchsc.edu

Authors and Affiliations

  1. GS Eisenbarth is Executive Director of the Barbara Davis Center for Childhood Diabetes at the University of Colorado, Aurora, CO, USA.,

    George S Eisenbarth

Authors
  1. George S Eisenbarth
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenbarth, G. Do NALP5 antibodies correlate with hypoparathyroidism in patients with APS-1?. Nat Rev Endocrinol 4, 544–545 (2008). https://doi.org/10.1038/ncpendmet0924

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0924

  • Springer Nature Limited

This article is cited by

Search

Navigation